RxDoctor Payments Data

Walter Taylor, MD

Neurology · Rockwall, TXNPI 1992709620

Payments from drug & device makers

$7,388in general payments, 2019–2025

Across 346 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$485
  • UCB, Inc.$465
  • SK Life Science, Inc.$357
  • Biogen$345
  • Novartis$324
  • plus $4K from 46 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$7,35199%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,388 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$1,185,980
Medicare patients
735
Services billed
26,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5020$374,712
IngrezzaValbenazine Tosylate15$194,804
UbrelvyUbrogepant97$137,901
Nurtec OdtRimegepant Sulfate54$90,078
Aimovig AutoinjectorErenumab-Aooe60$87,022
Austedo XrDeutetrabenazine12$60,033
RytaryCarbidopa/Levodopa38$54,890
NeuproRotigotine20$43,101
Emgality PenGalcanezumab-Gnlm34$34,740
QuliptaAtogepant21$23,324
Ajovy AutoinjectorFremanezumab-Vfrm14$21,900
Emgality SyringeGalcanezumab-Gnlm15$19,152
BotoxOnabotulinumtoxina14$18,532
AptiomEslicarbazepine Acetate12$16,674
NuedextaDextromethorphan Hbr/Quinidine11$16,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Dilantin$485$472,528101 claims
Neurocrine Biosciences, Inc.Ingrezza$151$194,80415 claims
AbbVieUbrelvy, Qulipta, Botox$1,009$179,756132 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$295$60,03312 claims
Amneal Pharmaceuticals LLCRytary$45$54,89038 claims
UCB, Inc.Neupro, Nayzilam$465$51,67533 claims
Sunovion Pharmaceuticals Inc.Aptiom$12$16,67412 claims
Upsher-smith Laboratories LLCTopiramate$33$1,422186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.

Other neurology in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →